Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Conditions
Keywords
Malignant Effusion Composition, Paracentesis, Thoracentesis, Natural History
Brief summary
Background: Researchers want to study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer. This may lead to better ways to treat cancer. Objectives: To study the biology of cancer. Eligibility: Adults 18 and older with malignant solid tumors. Design: Participants will be screened with medical history, blood tests, and confirmation of diagnosis. Participants will have samples taken at regularly scheduled procedures. Fluids from the abdomen and/or lungs will be taken as part of the procedures. Blood will be taken separately. Participants may be asked to give more samples at future procedures.
Detailed description
Background: -Malignant ascites or pleural effusions are often seen in patients with solid tumor malignancies. -Malignant ascites is proinflammatory with many cytokines present and acts to promote tumor cell growth. -The cellular composition of malignant ascites consists of lymphocytes, macrophages and monocytes. -Serum monocytes and lymphocytes play a role in the native host anti-tumor immune mediated mechanisms. -A paracentesis or thoracentesis is often done for symptomatic relief from the malignant fluid collection. Primary Objective: -To obtain blood samples and ascites and pleural effusion samples from patients with solid tumor malignancies, with the intent of performing translational studies related to cancer. Eligibility: * Patients greater than or equal to 18 years of age. * Diagnosis of malignant solid tumor. * Patients must be able and willing to provide informed consent. Design: -We will collect approximately 200cc-5L ascites from patients that are undergoing a therapeutic paracentesis or thoracentesis. No thoracentesis or paracentesis will be performed solely for research purposes. -The fluid will be collected during the medical procedure and may be collected at more than one time point. -We will also collect 30ml of peripheral blood. This will be from patients who are being seen in follow up, consultation, or presenting for enrollment on a clinical trial.
Interventions
None listed
Sponsors
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: * Participants greater than or equal to 18 years of age with histologically proven malignant solid tumors * Ability and willingness to provide informed consent to participation. * Participants with malignant solid tumors with a clinical indication for a thoracentesis or paracentesis.
Exclusion criteria
-Children \< 18 years of age are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To obtain blood samples, ascites and pleural effusion samples from patients with solid tumor malignancies, with the intent of performing translational studies related to cancer. | Ongoing | Experimental - Translational study outcomes from the collection/analysis of blood samples; and ascites and pleural effusion samples from patients with solid tumor malignancies. |
Secondary
| Measure | Time frame |
|---|---|
| Characterize malignant effusion composition through immunohistochemistry and flow cytometry. | ongoing |
| Compare immune cell phenotype in ascites and blood from the patient. | ongoing |
| Develop the malignant fluid as a culture model to replicate intraperitoneal growth of ovarian cancers. | ongoing |
| Establish a bank of clinically annotated samples for translational science. | ongoing |
| Compare selected matched sets of samples from the same patient to evaluate both for treatment response. | ongoing |
| Study in vivo characteristics of matched tumor cells and peripheral blood leukocytes from the same patient in xenograft models | ongoing |
Countries
United States
Outcome results
None listed